Aricept tablets are taken by mouth for symptoms of Alzheimer’s disease in adults. The active ingredient, donepezil, supports cholinergic signalling in the brain and may help preserve memory, attention, and daily functioning for a period of time.
Aricept tablets are taken by mouth for symptoms of Alzheimer’s disease in adults. The active ingredient, donepezil, supports cholinergic signalling in the brain and may help preserve memory, attention, and daily functioning for a period of time.
Donepezil reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. Higher acetylcholine activity can improve communication between nerve cells that remain functional. This may support cognition, orientation, language, and everyday tasks, although the degree of benefit varies between patients.
The effect is symptomatic rather than curative. Aricept does not restore damaged brain tissue or stop Alzheimer’s disease from progressing. Some patients show measurable improvement, while others mainly experience slower decline or more stable daily functioning.
The European Medicines Agency describes donepezil as an acetylcholinesterase inhibitor for Alzheimer’s dementia [1]. The clinical target is cognition and functioning, not a general stimulant effect. It should not be expected to produce immediate improvement after one tablet.
Donepezil differs from memantine. Donepezil increases acetylcholine activity, while memantine modulates excessive glutamate activity at NMDA receptors. Physicians may use one approach or combine mechanisms in moderate or severe disease when the clinical situation supports it.
Aricept contains donepezil, a centrally acting acetylcholinesterase inhibitor.
The prescribed amount is set individually. Treatment commonly begins with a lower daily amount, followed by adjustment when tolerability and clinical response have been assessed. Aricept is supplied as tablets for oral use.
The drug is intended for adults diagnosed with Alzheimer’s disease. A relative or caregiver often helps with daily administration because memory impairment can make missed or repeated doses more likely.
The amount per intake is selected for each person rather than being one fixed amount for every patient. Doctors usually consider disease severity, previous treatment, kidney and liver function, other medicines, pulse rate, body weight, and gastrointestinal tolerance.
A forgotten dose should not be “made up” with an extra dose. With Alzheimer’s treatment, the practical danger is often double administration by two different caregivers. One person should take responsibility for recording each dose.
Tablets should be swallowed as directed. Do not crush, split, or chew a tablet unless the treating clinician has confirmed that the specific formulation can be handled that way.
Aricept is not suitable for a person with a previous serious allergic reaction to donepezil, piperidine derivatives, or any tablet ingredient.
Medical review is needed before treatment when the patient has:
Donepezil may interact with beta-blockers, some calcium-channel blockers, antiarrhythmic medicines, and other treatments that slow cardiac conduction. Anticholinergic medicines can oppose its effects and may worsen cognition, constipation, dry mouth, or urinary retention.
Some medicines can increase donepezil exposure by inhibiting CYP3A4 or CYP2D6. Other medicines can lower exposure by inducing these enzymes.
Aricept is not for you if you have had such a reaction; seek medical advice about alternatives. It also requires careful assessment in several medical situations.
Digestive symptoms are among the most familiar adverse effects of donepezil. Nausea, diarrhoea, vomiting, abdominal discomfort, and reduced appetite may appear after starting treatment or after an increase in the prescribed amount. These symptoms may improve as the body adapts, but persistent vomiting or dehydration requires prompt medical review.
Other possible effects include:
A slower pulse can be clinically significant in a patient with conduction disease, sick sinus syndrome, or treatment with medicines that also reduce heart rate. Fainting, new falls, chest discomfort, severe weakness, or an unusually slow pulse need urgent assessment.
Vomiting, black stools, vomiting blood, or severe abdominal pain can signal gastrointestinal bleeding or ulcer complications. Donepezil may increase gastric acid and cholinergic activity, so the risk deserves attention in patients with a history of ulcers or regular anti-inflammatory painkiller use.
Some patients report vivid dreams when taking Aricept at night. A morning schedule may reduce this problem, but changing the timing should be coordinated with the prescriber rather than paired with an extra dose.
The U.S. prescribing information lists gastrointestinal reactions, muscle cramps, insomnia, fatigue, dizziness, and bradycardia among recognised adverse effects [2]. The practical question is whether a symptom is mild and temporary or whether it is changing hydration, mobility, sleep, or safety.
It is used for symptomatic treatment of mild, moderate, and severe Alzheimer’s dementia.
| Treatment approach | Main pharmacological action | Typical clinical role |
|---|---|---|
| Donepezil | Inhibits acetylcholinesterase and increases acetylcholine activity | Symptomatic treatment across Alzheimer’s disease stages |
| Memantine | Modulates NMDA receptor activity and glutamate signalling | Often considered in moderate or severe disease |
| Combined mechanism | Uses cholinergic support with NMDA modulation | May be considered when symptoms and treatment response justify it |
Donepezil is often selected when memory and cognitive symptoms are the main treatment target. Memantine may become more relevant as Alzheimer’s disease advances, especially when functional impairment and behavioural symptoms increase. Combined therapy can add complexity and may increase the need for monitoring.
The choice is not based only on memory test results. Falls, fainting, low pulse, weight loss, sleep disturbance, urinary symptoms, gastrointestinal disease, and the medicines already being used all affect the balance of treatment.
Donepezil is not expected to produce a same-day improvement. Assessing the response requires consistent use and observations over time. A single difficult day does not prove treatment failure.
Taking an extra tablet can increase nausea, dizziness, muscle cramps, fainting, and slow pulse. The missed-dose plan should be written down for every caregiver involved.
Moving between morning and evening doses can make adherence difficult and may complicate the interpretation of sleep problems. One stable schedule is easier to monitor.
Reduced appetite can seem minor at first. Continued weight loss may contribute to weakness, falls, and poorer recovery from illness.
Over-the-counter sleep aids, bladder medicines, anti-inflammatory painkillers, and heart-rate-lowering medicines may alter the risk profile. Every regular medicine and supplement should be included in the medication list.
Mild nausea may settle, while severe vomiting, dehydration, abdominal bleeding, or fainting requires immediate medical attention. The response should match the symptom rather than treating every reaction the same way.
In clinical practice, doctors often judge Aricept by function rather than by a dramatic memory change. A patient who remains able to dress independently, prepare a familiar meal, or follow a daily routine may be receiving meaningful benefit even when formal testing shows only modest change.
A physician will usually look for a baseline before treatment begins. Useful observations include medication management, ability to hold a conversation, orientation outside the home, continence, sleep, appetite, and the frequency of falls. These details help distinguish treatment response from ordinary day-to-day variation.
Treatment review also includes the caregiver’s experience. If the patient is more alert but has persistent diarrhoea, weight loss, fainting, or severe insomnia, the clinical balance may be unfavourable. A lower dose, a timing change, or a different treatment plan may be considered.
The World Health Organization places dementia care within a broader plan that includes cognitive support, physical activity, caregiver education, and management of cardiovascular risk [3]. Medication works within that plan; it does not replace it.
Store Aricept tablets in a dry place at ordinary room temperature, away from excessive heat and moisture. Keep the medicine secured from children and from a person who may accidentally take an extra dose because of memory impairment. During travel, keep the tablets with the person’s essential medicines rather than leaving them in a hot vehicle. The EMA's 2024 packaging guidance and the approved product information support protection from unsuitable heat and moisture [4].
Aricept is intended for Alzheimer’s disease in adults, and routine use in people under 18 is not established. Memory problems in a younger person require assessment for causes that differ from typical Alzheimer’s disease. A child or adolescent should not receive donepezil from another person’s prescription. WHO dementia guidance published in 2023 supports age-appropriate diagnostic assessment before treatment decisions are made.
The discussion should include fainting, slow pulse, heart rhythm problems, ulcers, asthma, seizures, urinary obstruction, liver disease, swallowing problems, weight loss, and previous drug allergies. Provide a full list of prescription medicines, over-the-counter products, and supplements, including beta-blockers, bladder medicines, sedatives, and anti-inflammatory painkillers. The doctor should also know who will administer the tablets and how treatment response will be monitored. MOHAP medication-safety principles published in 2024 support complete medication reconciliation before starting a new long-term treatment.
Regular sleep, physical activity suited to the patient’s mobility, hydration, and familiar daily routines can support independence and reduce confusion. Meals should provide enough calories and protein when appetite is reduced. Excess alcohol can worsen dizziness, falls, and confusion, while dehydration can intensify weakness and constipation. NICE dementia guidance from 2022 recommends personalised activity, nutritional support, and caregiver involvement alongside drug treatment.
Aricept may be combined with other treatments only after the full medication list has been reviewed. Medicines that slow the heart, anticholinergic medicines, CYP3A4 or CYP2D6 inhibitors, enzyme-inducing medicines, sedatives, and regular anti-inflammatory painkillers can change the risks or expected response. Supplements also matter when they affect alertness, heart rate, bleeding risk, or digestion. The FDA's 2022 prescribing information advises reviewing interacting medicines and monitoring for fainting, gastrointestinal symptoms, and changes in pulse [2].
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
